Sofosbuvir and simeprevir is effective for recurrent hepatitis C in liver transplant recipients
Sofosbuvir and simeprevir is effective for recurrent hepatitis C in liver transplant recipients
复制标题
DOI：
10.1111/liv.12856
复制
发表时间：
2015-11-01
影响因子：
6.7
通讯作者：
Busuttil, Ronald W.
中科院分区：
文献类型：
--
作者：
Saab, Sammy;Greenberg, Adam;Busuttil, Ronald W.
背景与目的丙型肝炎是肝移植最常见的适应症.复发性感染是普遍的，可导致进行性肝病。广泛使用的干扰素为基础的治疗已受到限制的不耐受性和不良反应。MethodsWe回顾性评估的安全性，耐受性和疗效sofosbuvir和simeprevir在治疗复发性丙型肝炎的成人（年龄>18）LT recipients. Results76%的收件人是男性和平均年龄[标准差（SD）]为61（6.0）岁。从LT至治疗开始的平均时间（+/- SD）为71.8（+/- 77.1）个月。在开始抗病毒治疗后4周测量病毒水平的26名患者中，58%无法检测到。在治疗结束时，所有移植受者的病毒载量均检测不到。12周持续病毒应答率（SVR）为93%。所有受者都能够完成治疗，没有患者在治疗期间需要输血生长因子。没有病人需要中断药物的免疫抑制剂therapy.ConclusionThe使用sofosbuvir和simeprevir是有效的，安全的，和耐受的，并应考虑在LT收件人复发HCV谁是抗病毒治疗的候选人。
Background & AimsHepatitis C is the most common indication for liver transplantation (LT). Recurrent infection is universal and can lead to progressive liver disease. Widespread use of interferon-based therapy has been limited by intolerability and adverse effects.MethodsWe retrospectively evaluated the safety, tolerability, and efficacy of sofosbuvir and simeprevir in the treatment of recurrent hepatitis C in adult (age >18) LT recipients.ResultsSeventy-six percent of the recipients were male and the mean age [standard deviation (SD)] was 61 (6.0) years. The mean time (+/- SD) from LT to treatment initiation was 71.8 (+/- 77.1) months. Of the 26 patients with viral levels measured 4weeks after starting antiviral therapy, 58% were undetectable. At the end of therapy, viral load was undetectable in all transplant recipients. The 12week sustained viral response (SVR) was 93%. All recipients were able to complete therapy and no patients required growth factors of blood product transfusion during treatment. No patient required drug interruption of their immunosuppressant therapy.ConclusionThe use of sofosbuvir and simeprevir is efficacious, safe, and tolerable and should be considered in LT recipients with recurrent HCV who are candidates for antiviral therapy.See Editorial on Page 2354